CSH MEDI, a Shanghai-based biomagnetic equipment manufacturer, has reportedly raised close to RMB 100 million (USD 13.8 million) in a Series A+ financing round. The sole investor in this round was XinDing Capital. The proceeds from this funding will be allocated towards research and development, as well as the iteration of magnetocardiogram technology. Additionally, the funds will support large magnetocardiogram (MCG) clinical studies and the clinical filing for fetal magnetocardiogram (fMCG) for early congenital heart disease examination.
Establishment and Background of CSH MEDI
Established in 2009, CSH MEDI was founded on the National High-tech R&D Program of China, also known as the 863 Program. This program is a significant initiative aimed at driving innovation and technological advancement in China. CSH MEDI’s establishment is a testament to the company’s commitment to leveraging advanced technology for medical applications.
Implications for Biomagnetic Equipment and Diagnostics
The investment in CSH MEDI underscores the growing interest in biomagnetic equipment and its potential applications in healthcare. The development of magnetocardiogram technology and the focus on fetal cardiovascular diagnostics highlight the company’s mission to improve early detection and treatment of congenital heart diseases. With the support of XinDing Capital, CSH MEDI is poised to make significant strides in the field of biomagnetic diagnostics.-Fineline Info & Tech
